A new SEC filing reveals that CHRISTOPHER HOLLAND , Board Member at Steris (NYSE: STE ), made a notable insider purchase on August 12,. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that HOLLAND purchased 988 shares of Steris. The total transaction amounted to $236,803. Monitoring the market, Steris ''s shares down by 0.0% at $233.94 during Tuesday''s morning. Get to Know Steris Better Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.

STE''s Q1 FY''25 numbers were in line with expectations, with upsides in the healthcare and AST divisions. Read more about STE stock here.

STERIS plc (NYSE: STE ) reported first-quarter fiscal 2025 adjusted earnings per share of $2.03, up 10.3% from the year-ago quarter''s figure. The figure surpassed the Zacks Consensus Estimate by 2 cents. The adjustment excludes the impacts of certain non-recurring charges, such as the amortization of acquired intangible assets and acquisition and integration-related charges, among others. The company''s GAAP EPS was $1.41, up 7.6% from the year-ago level of $1.31. Revenues in Detail Revenues of $1.28 billion from continuing operations increased 8.5% year over year. The figure outpaced the Zacks Consensus Estimate by 1.5%. Organic revenues at the constant exchange rate or CER rose 6% year over year. Quarter in Detail The company operates through three segments — Healthcare, Applied Sterilization Technologies ("AST"), and Life Sciences. Revenues at Healthcare rose 10% year over year to $901.2 million (up 5% on a CER organic basis). While there was a 23% improvement in consumable revenues and a 14% increase in service revenues, these were partially offset by a 10% decline in capital equipment revenues.

STERIS plc (NYSE:NYSE:STE) Q1 2025 Earnings Conference Call August 7, 2024 9:00 AM ETCompany ParticipantsJulie Winter - Investor RelationsMike Tokich -…

No summary available.

WASHINGTON (dpa-AFX) - STERIS plc (STE) released earnings for its first quarter that increased from the same period last year and beat the Street estimates.The company''s earnings came in at $145.4…

DUBLIN, IRELAND , Aug. 06, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2025 first quarter ended June 30, 2024. Total revenue from continuing operations for the first quarter of fiscal 2025 increased 8% to $1.3 billion compared with $1.2 billion in the first quarter of fiscal 2024. Constant currency organic revenue from continuing operations for the first quarter increased 6%.

STERIS reports strong Q1 FY2025: Revenue up 8% to $1.3B, adjusted EPS rises to $2.03. Healthcare segment shines with 10% growth. Company reaffirms optimistic full-year outlook despite challenges in Life Sciences.

https://www.investing.com/news/company-news/steris-plc-shareholders-approve-board-and-auditor-proposals-93CH-3550517

BURLINGAME, CALIFORNIA, UNITED STATES, July 25, 2024 /⁨EINPresswire.com⁩/ -- Coherent Market Insights Published the Latest Bio Decontamination Market Study by in-depth analysis of the current scenario, the Market size, demand, growth pattern, …